The study, whose innovative design is meant to find out — fast — what works, began at the end of February with the anti-viral drug remdesivir made by Gilead Sciences. Jennifer Routh, a spokeswoman at the National Institute of Allergy and Infectious Diseases, confirmed that the drug would now be tested in the federal trial but said the institute could offer no further comment. Benevolent AI also noted another potential advantage of baricitinib, said Dr. Vincent Marconi of Emory University, a principal investigator in the federal trial. The warning label on the drug, he added, “tempered our enthusiasm.”As COVID-19 spread, some doctors started giving patients the drug anyway. It is really hard to interpret those kinds of data.”The company realised it had to accept the offer to contribute its drug for the federal trial.

Source: bd News24 April 14, 2020 06:45 UTC